Spinal Muscular Atrophy (SMA) is often called the "invisible epidemic" because its impact is as varied as it is devastating. Unlike conditions that immediately signal danger (like congenital heart defects), SMA presents with subtle symptoms that may go unnoticed for months or years. This delayed diagnosis is particularly critical in regions like Northeast India, where healthcare access is limited and pediatric neurological services are scarce.

According to the Global Burden of Disease Study (2019), SMA affects approximately 1 in 10,000 live births worldwide, with Type 1 SMA—the most severe form—accounting for about 70% of cases. However, the actual incidence may be higher due to underreporting in low-resource settings. In India alone, estimates suggest there are around 15,000-20,000 SMA patients, yet only a fraction receive proper diagnosis and treatment. The regional disparity is stark: while urban centers like Mumbai and Delhi have specialized pediatric neuromuscular clinics, the Northeast remains largely untouched by this medical revolution.

The genetic basis of SMA lies in mutations of the SMN1 gene, which produces survival motor neuron (SMN) protein essential for motor neuron function. The SMN2 gene, which is nearly identical, serves as a backup. However, in SMA patients, the SMN2 gene is often insufficient to compensate for the loss of SMN1. Risdiplam works by increasing SMN2 expression through a novel mechanism—it binds to a region of the SMN2 gene that isn't affected by the SMA mutation, allowing the gene to produce more functional SMN protein.

This distinction is crucial. While Spinraza targets the SMN1 gene directly, Risdiplam's approach is more systemic. Clinical trials have shown that Risdiplam can achieve higher and more sustained levels of SMN protein than Spinraza, potentially offering better outcomes for patients with milder forms of SMA. The FDA approved Risdiplam in 2020, and European approval followed in 2021, but its availability in India has been limited by regulatory hurdles and pricing considerations.

The introduction of oral therapy in Northeast India isn't just a local achievement—it's a potential blueprint for how rare disease care should be delivered globally. The region's unique challenges—limited healthcare infrastructure, cultural barriers to medical access, and economic constraints—mirror many developing countries where rare diseases are often overlooked. If successful, this model could demonstrate that rare disease care doesn't require advanced medical facilities or expensive infrastructure; rather, it requires thoughtful, adaptive approaches to treatment delivery.

Consider the lessons from other regions. In Brazil, where SMA affects approximately 1 in 10,000 births, the government has begun implementing a national program to screen newborns for SMA. However, the program faces significant challenges in rural areas, where many families lack access to prenatal care. The Northeast Indian experience suggests that even in regions with limited resources, targeted interventions can make a difference.

The oral route of administration also opens up new possibilities for patient advocacy and community engagement. Unlike injectable therapies that require frequent clinic visits, oral treatments could enable patients to receive care in their homes, reducing the stigma associated with medical treatment. This is particularly important in cultures where open medical care is still considered taboo. In Northeast India, where many families live in remote villages, the ability to administer treatment at home could transform the way SMA patients are cared for.

The Northeast Indian experience also raises important questions about the role of public-private partnerships in rare disease care. While the National Policy for Rare Diseases provides a framework, its implementation depends on collaboration between government agencies, pharmaceutical companies, and healthcare providers. The success of oral therapy in Northeast India could serve as a model for how such partnerships should be structured, particularly in regions where healthcare systems are underfunded.

One critical implication is the need for regionalized healthcare strategies. Rather than treating rare diseases as isolated medical problems, healthcare systems should consider how treatments can be adapted to local contexts. In Northeast India, this means developing regional networks of pediatric neurologists, genetic counselors, and support groups. It also means creating training programs for healthcare workers to administer oral therapies effectively.